This is the authors' abstract. We don't add key points for this paper.
Active center-directed peptide inhibitors of plasmin were designed based on the structure of specific substrates of plasmin and synthesized by a conventional solution method. Their effects on plasmin were examined and the structure-activity relationship was studied. D-Ile-Phe-Lys-BZA (4-benzoylanilide) inhibited plasmin activities toward S-2251 and fibrin (IC50 : 0.069mM and 0.18mM respectively) but D-Ile-Phe-Lys-BPP (4-benzylpiperidine amide) was not inhibitory. However D-Ile-Phe-Lys-BZA was cleaved by plasmin to release benzoylaniline, indicating that this type of peptide inhibitor is not stable to plasmin. It was found that Tos-Lys-pNA was not cleaved by palsmin and inhibited plasmin activity toward not only fibrin but also amall peptide substrates and fibrinogen by blocking the active center of plasmin with some selectivity. In order to obtain potent and stable inhibitors of plasmin, it is recommended to design them with reference to the structures of Tos-Lys-pNA and the specific substrate, D-Ile-Phe-Lys-pNA.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Okada et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: